Tao Synergies Inc (TAOX)

$5.95 +0.31 (5.50%)
Market Cap 43.20M
Revenue (ttm) 0.00
Net Income (ttm) -12.77M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 344,400
Avg Vol 154,812
Day's Range N/A - N/A
Shares Out 7.45M
Stochastic %K 71%
Beta 1.99
Analysts Strong Buy
Price Target N/A

Company Profile

TAO Synergies Inc. owns and operates an AI token. The company executes a cryptocurrency treasury strategy centered on the acquisition and staking of the TAO token, the native utility token of the Bittensor network. TAO Synergies Inc. was formerly known as Synaptogenix, Inc. and changed its name to TAO Synergies Inc. in June 2025. The company was incorporated in 2012 and is headquartered in New York, New York.

Industry: Software - Infrastructure
Sector: Technology
Phone: 973 242 0005
Address:
1185 Avenue of the Americas, 3rd Floor, New York, United States
EndGame1
EndGame1 Mar. 20 at 9:58 PM
$TAOX Bounced at $270. Let’s see what Monday brings? https://www.coingecko.com/en/coins/bittensor
0 · Reply
EndGame1
EndGame1 Mar. 20 at 6:34 PM
$TAOX $TAO.X coin from $245/coin to $301 overnight. Back to $270's. Soon reverses back to chase $300 over the weekend.
1 · Reply
EndGame1
EndGame1 Mar. 20 at 6:28 PM
$TAOX Look at that current $.30 spread. $5.77 bid $6.07 ask. This is still thin for now.
0 · Reply
topstockalerts
topstockalerts Mar. 20 at 5:25 PM
$TAOX newer name behavior, still in discovery mode. Those can go either way fast once traders lock in.
0 · Reply
EndGame1
EndGame1 Mar. 20 at 3:18 PM
$DGXX I'm spreading the word on Digi Power and my other horses $TAOX $SOFI $BLNE
0 · Reply
EndGame1
EndGame1 Mar. 20 at 2:29 PM
$TAOX We closed that daily gap up from $5.80. Now back to $6's. Finally getting noticed.
0 · Reply
EndGame1
EndGame1 Mar. 20 at 1:44 AM
$TAOX And just like that. Never sell $TAO.X coin. Bittensor TAO Price #35 $279.70 23.6% (7d
0 · Reply
EndGame1
EndGame1 Mar. 19 at 2:26 PM
$TAOX Ugly couple of days. I'm just holding for the bounce back.
0 · Reply
Ineedbenjamins
Ineedbenjamins Mar. 18 at 6:45 PM
$TAOX Aixbt said this
0 · Reply
EndGame1
EndGame1 Mar. 18 at 4:14 PM
$TAOX Price is down, but $TAO.X coin still holding #38 spot. Was 55 a few weeks ago. Bittensor TAO Price #38 $268.52 35.2% (7d)
0 · Reply
Latest News on TAOX
Options Trading Now Available on Tradr's BEX, CSEX, NNEX & SNPXcsex

Nov 18, 2025, 5:15 PM EST - 4 months ago

Options Trading Now Available on Tradr's BEX, CSEX, NNEX & SNPXcsex

BEX CSEX NNEX SNPX

TAO Synergies and Yuma Asset Management to Host Livestream on X: Bittensor (TAO) and DeAI Innovation

Nov 18, 2025, 9:15 AM EST - 4 months ago

TAO Synergies and Yuma Asset Management to Host Livestream on X: Bittensor (TAO) and DeAI Innovation

Tradr Expands Leveraged Lineup With 4 New Single-Stock ETFs Targeting AI Infrastructure Firms

Nov 13, 2025, 1:37 PM EST - 4 months ago

Tradr Expands Leveraged Lineup With 4 New Single-Stock ETFs Targeting AI Infrastructure Firms

BEX CSEX NNEX SNPX

Tradr Launches Leveraged ETFs on Bloom Energy, Celestica, NANO Nuclear & Synopsys

Nov 13, 2025, 6:46 AM EST - 4 months ago

Tradr Launches Leveraged ETFs on Bloom Energy, Celestica, NANO Nuclear & Synopsys

BEX CSEX NNEX SNPX

Tradr Set to Debut ETFs Targeting Bloom Energy, Celestica, Nano Nuclear and Synopsys

Nov 11, 2025, 11:26 AM EST - 4 months ago

Tradr Set to Debut ETFs Targeting Bloom Energy, Celestica, Nano Nuclear and Synopsys

BEX CSEX NNEX SNPX

TAO Synergies Announces Initial $750,000 Investment in Yuma Asset Management's Subnet Funds

Nov 4, 2025, 9:15 AM EST - 4 months ago

TAO Synergies Announces Initial $750,000 Investment in Yuma Asset Management's Subnet Funds

TAO Synergies Raises Bittensor (TAO) Holdings to over 54,000 Tokens, Largest Publicly Traded Holder of Top Decentralized AI Cryptocurrency

Oct 20, 2025, 9:15 AM EDT - 5 months ago

TAO Synergies Raises Bittensor (TAO) Holdings to over 54,000 Tokens, Largest Publicly Traded Holder of Top Decentralized AI Cryptocurrency

TAO Synergies Announces $11 Million Private Placement

Oct 13, 2025, 5:09 PM EDT - 5 months ago

TAO Synergies Announces $11 Million Private Placement

TAO Synergies Launches "The TAO Daily," the Premier Media Platform for All Things Bittensor (TAO)

Sep 22, 2025, 9:15 AM EDT - 6 months ago

TAO Synergies Launches "The TAO Daily," the Premier Media Platform for All Things Bittensor (TAO)

TAO Synergies Digital Assets Advisor James Altucher Speaks at Google's Planet Scale Consumer AI Event

Sep 8, 2025, 9:15 AM EDT - 6 months ago

TAO Synergies Digital Assets Advisor James Altucher Speaks at Google's Planet Scale Consumer AI Event

TAO Synergies Welcomes Top Bittensor (TAO) Leader as Advisor for AI-Focused Crypto Treasury Strategy

Aug 26, 2025, 9:15 AM EDT - 7 months ago

TAO Synergies Welcomes Top Bittensor (TAO) Leader as Advisor for AI-Focused Crypto Treasury Strategy

TAO Synergies (Formerly Synaptogenix) Begins Trading Under New Nasdaq Stock Symbol "TAOX" Effective at Market Open Today

Jul 1, 2025, 9:15 AM EDT - 9 months ago

TAO Synergies (Formerly Synaptogenix) Begins Trading Under New Nasdaq Stock Symbol "TAOX" Effective at Market Open Today

Synaptogenix Announces Name Change to TAO Synergies and New Ticker Symbol "TAOX" for Alignment with AI-Focused Crypto Treasury Strategy

Jun 26, 2025, 9:15 AM EDT - 9 months ago

Synaptogenix Announces Name Change to TAO Synergies and New Ticker Symbol "TAOX" for Alignment with AI-Focused Crypto Treasury Strategy

Synaptogenix Announces Initial TAO Acquisition under Crypto Treasury Strategy, Appoints BitGo as Custodian, and Commences Yield Generation Through Staking

Jun 24, 2025, 9:15 AM EDT - 9 months ago

Synaptogenix Announces Initial TAO Acquisition under Crypto Treasury Strategy, Appoints BitGo as Custodian, and Commences Yield Generation Through Staking

Synaptogenix Appoints Crypto Expert to Lead Digital Asset Treasury Strategy Focused Exclusively on Top-Valued AI Token

Jun 9, 2025, 9:00 AM EDT - 10 months ago

Synaptogenix Appoints Crypto Expert to Lead Digital Asset Treasury Strategy Focused Exclusively on Top-Valued AI Token

Synaptogenix Board of Directors Forms Special Committee to Explore Value Creation Opportunities Utilizing Balance Sheet Strength

Dec 20, 2024, 9:15 AM EST - 1 year ago

Synaptogenix Board of Directors Forms Special Committee to Explore Value Creation Opportunities Utilizing Balance Sheet Strength

Synaptogenix Announces $5.0 Million Financing

Sep 11, 2024, 9:00 AM EDT - 1 year ago

Synaptogenix Announces $5.0 Million Financing

Synaptogenix Announces New Collaboration with LSU Health New Orleans for Study of Proprietary Analogs in Spinal Cord Injury

Jul 18, 2024, 9:00 AM EDT - 1 year ago

Synaptogenix Announces New Collaboration with LSU Health New Orleans for Study of Proprietary Analogs in Spinal Cord Injury

Synaptogenix Announces FDA Authorization of IND Application for Clinical Trial for Bryostatin-1 in Multiple Sclerosis

Jun 26, 2024, 9:00 AM EDT - 1 year ago

Synaptogenix Announces FDA Authorization of IND Application for Clinical Trial for Bryostatin-1 in Multiple Sclerosis

Synaptogenix Applauds DEA Proposal to Reclassify Cannabis and Shares Expected Benefits to Cannasoul for Cannabinoid-Based Drug Discovery

May 7, 2024, 9:00 AM EDT - 2 years ago

Synaptogenix Applauds DEA Proposal to Reclassify Cannabis and Shares Expected Benefits to Cannasoul for Cannabinoid-Based Drug Discovery

Synaptogenix Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing

Apr 24, 2024, 9:15 AM EDT - 2 years ago

Synaptogenix Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing

Synaptogenix Announces Reverse Stock Split to Maintain Nasdaq Listing

Apr 3, 2024, 8:00 AM EDT - 2 years ago

Synaptogenix Announces Reverse Stock Split to Maintain Nasdaq Listing

Synaptogenix President Daniel L. Alkon, M.D.

Dec 19, 2023, 9:00 AM EST - 2 years ago

Synaptogenix President Daniel L. Alkon, M.D.

Synaptogenix Joins Leading Neuroscientists and Academics as Speaker at USC-Sponsored Forum on Age-Related Diseases including Alzheimer's

Dec 6, 2023, 9:00 AM EST - 2 years ago

Synaptogenix Joins Leading Neuroscientists and Academics as Speaker at USC-Sponsored Forum on Age-Related Diseases including Alzheimer's

Synaptogenix Acquires Significant Stake in Cannasoul Analtyics Ltd. Co-founded by The Technion - Israel Institute of Technology

Nov 2, 2023, 9:00 AM EDT - 2 years ago

Synaptogenix Acquires Significant Stake in Cannasoul Analtyics Ltd. Co-founded by The Technion - Israel Institute of Technology

Synaptogenix Announces Peer-Reviewed Publication of NIH-Sponsored Phase 2 Clinical Trial Results Demonstrating Safe, Significant, and Persistent Benefits of Bryostatin-1 in Advanced Alzheimer's Disease

Sep 26, 2023, 9:00 AM EDT - 2 years ago

Synaptogenix Announces Peer-Reviewed Publication of NIH-Sponsored Phase 2 Clinical Trial Results Demonstrating Safe, Significant, and Persistent Benefits of Bryostatin-1 in Advanced Alzheimer's Disease

Bryostatin-1 from Synaptogenix Shows Statistically Significant Results as an ALS Treatment in Pre-Clinical Independent Study

Sep 7, 2023, 9:00 AM EDT - 2 years ago

Bryostatin-1 from Synaptogenix Shows Statistically Significant Results as an ALS Treatment in Pre-Clinical Independent Study

Synaptogenix and Cleveland Clinic to Submit Investigational New Drug (IND) Application to FDA for Clinical Trial of Bryostatin-1 in Multiple Sclerosis

Jul 19, 2023, 9:00 AM EDT - 2 years ago

Synaptogenix and Cleveland Clinic to Submit Investigational New Drug (IND) Application to FDA for Clinical Trial of Bryostatin-1 in Multiple Sclerosis

Synaptogenix Abstract Highlighting Bryostatin-1 Benefits in Severe Alzheimer's Disease Accepted for Presentation at 11th International Brain Research Organization World Congress of Neuroscience

Jul 13, 2023, 9:00 AM EDT - 2 years ago

Synaptogenix Abstract Highlighting Bryostatin-1 Benefits in Severe Alzheimer's Disease Accepted for Presentation at 11th International Brain Research Organization World Congress of Neuroscience

Synaptogenix Provides Corporate Update and Outlines Potential Business Opportunities

Mar 7, 2023, 9:00 AM EST - 3 years ago

Synaptogenix Provides Corporate Update and Outlines Potential Business Opportunities

5 Health Care Stocks That Are Diving - And May Rally

Jan 19, 2023, 8:58 AM EST - 3 years ago

5 Health Care Stocks That Are Diving - And May Rally

FATE IPSC TECH

Synaptogenix Announces Topline Results from NIH-Sponsored Phase 2 Clinical Trial of Bryostatin-1 for Advanced Alzheimer's Disease

Dec 16, 2022, 9:00 AM EST - 3 years ago

Synaptogenix Announces Topline Results from NIH-Sponsored Phase 2 Clinical Trial of Bryostatin-1 for Advanced Alzheimer's Disease

Synaptogenix Announces $15 Million Private Placement with Existing Investors

Nov 18, 2022, 9:00 AM EST - 3 years ago

Synaptogenix Announces $15 Million Private Placement with Existing Investors

Synaptogenix to Present at ThinkEquity Investor Conference on October 26, 2022

Oct 19, 2022, 9:00 AM EDT - 3 years ago

Synaptogenix to Present at ThinkEquity Investor Conference on October 26, 2022

Synaptogenix Welcomes Lecanemab Phase 3 Trial Results

Sep 28, 2022, 11:50 AM EDT - 3 years ago

Synaptogenix Welcomes Lecanemab Phase 3 Trial Results

Synaptogenix Announces Live Appearance of its President and CSO on Streaming Financial News Network

Aug 12, 2022, 9:00 AM EDT - 3 years ago

Synaptogenix Announces Live Appearance of its President and CSO on Streaming Financial News Network

Synaptogenix Announces Changes to Scientific Advisory Board in Preparation for Phase 2 Data

Jul 26, 2022, 9:15 AM EDT - 3 years ago

Synaptogenix Announces Changes to Scientific Advisory Board in Preparation for Phase 2 Data

Synaptogenix Announces Corporate Update Conference Call

Jul 21, 2022, 9:15 AM EDT - 3 years ago

Synaptogenix Announces Corporate Update Conference Call

Synaptogenix Advances Dosing of First Patient in Dose Optimization Clinical Trial in Preparation for NIH-Sponsored, Phase 2 Alzheimer's Disease Trial Data

Jul 20, 2022, 9:15 AM EDT - 3 years ago

Synaptogenix Advances Dosing of First Patient in Dose Optimization Clinical Trial in Preparation for NIH-Sponsored, Phase 2 Alzheimer's Disease Trial Data

Synaptogenix to Present at the Cell Symposium

May 17, 2022, 9:15 AM EDT - 4 years ago

Synaptogenix to Present at the Cell Symposium

Synaptogenix Completes Patient Enrollment in NIH Sponsored Phase 2b Alzheimer's Disease Trial

Apr 19, 2022, 9:15 AM EDT - 4 years ago

Synaptogenix Completes Patient Enrollment in NIH Sponsored Phase 2b Alzheimer's Disease Trial

New Peer Reviewed Article Demonstrates Extended Therapeutic Potential of Synaptogenix's Bryostatin for Alzheimer's Disease

Apr 5, 2022, 9:15 AM EDT - 4 years ago

New Peer Reviewed Article Demonstrates Extended Therapeutic Potential of Synaptogenix's Bryostatin for Alzheimer's Disease

Synaptogenix to Present at Hanson Wade 10th Annual Neurodegenerative Drug Development Summit

Mar 29, 2022, 9:15 AM EDT - 4 years ago

Synaptogenix to Present at Hanson Wade 10th Annual Neurodegenerative Drug Development Summit

Synaptogenix to Present at Sachs 5th Annual Neuroscience Innovation Forum

Mar 22, 2022, 9:15 AM EDT - 4 years ago

Synaptogenix to Present at Sachs 5th Annual Neuroscience Innovation Forum

Synaptogenix to Present Research Highlighting Potential Broad Applicability for Lead Compound Bryostatin at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2022)

Mar 15, 2022, 9:15 AM EDT - 4 years ago

Synaptogenix to Present Research Highlighting Potential Broad Applicability for Lead Compound Bryostatin at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2022)

Synaptogenix Moves Forward with Clinical Development Plans for Bryostatin-1 as a Treatment for Multiple Sclerosis

Feb 23, 2022, 9:15 AM EST - 4 years ago

Synaptogenix Moves Forward with Clinical Development Plans for Bryostatin-1 as a Treatment for Multiple Sclerosis

Synaptogenix Announces Publication of Peer-Reviewed Scientific Article Evidencing Byrostatin-1's Improved Cognition Over Baseline in Advanced Alzheimer's Disease Patients

Feb 1, 2022, 9:15 AM EST - 4 years ago

Synaptogenix Announces Publication of Peer-Reviewed Scientific Article Evidencing Byrostatin-1's Improved Cognition Over Baseline in Advanced Alzheimer's Disease Patients

5 Short Squeeze Candidates To Watch: Huadi Tops List, Altimeter Group And Bit Digital Rejoin Leaderboard

Nov 15, 2021, 9:28 AM EST - 4 years ago

5 Short Squeeze Candidates To Watch: Huadi Tops List, Altimeter Group And Bit Digital Rejoin Leaderboard

BTBT HUDI

Rebuilding Connections, Fostering Growth: Synaptogenix Could Be A Beacon of Hope for Patients With Neurological Diseases

Oct 5, 2021, 9:14 AM EDT - 4 years ago

Rebuilding Connections, Fostering Growth: Synaptogenix Could Be A Beacon of Hope for Patients With Neurological Diseases

Synaptogenix Announces Participation at the H.C. Wainwright 23rd Annual Global Investment Conference

Sep 10, 2021, 9:00 AM EDT - 4 years ago

Synaptogenix Announces Participation at the H.C. Wainwright 23rd Annual Global Investment Conference

EndGame1
EndGame1 Mar. 20 at 9:58 PM
$TAOX Bounced at $270. Let’s see what Monday brings? https://www.coingecko.com/en/coins/bittensor
0 · Reply
EndGame1
EndGame1 Mar. 20 at 6:34 PM
$TAOX $TAO.X coin from $245/coin to $301 overnight. Back to $270's. Soon reverses back to chase $300 over the weekend.
1 · Reply
EndGame1
EndGame1 Mar. 20 at 6:28 PM
$TAOX Look at that current $.30 spread. $5.77 bid $6.07 ask. This is still thin for now.
0 · Reply
topstockalerts
topstockalerts Mar. 20 at 5:25 PM
$TAOX newer name behavior, still in discovery mode. Those can go either way fast once traders lock in.
0 · Reply
EndGame1
EndGame1 Mar. 20 at 3:18 PM
$DGXX I'm spreading the word on Digi Power and my other horses $TAOX $SOFI $BLNE
0 · Reply
EndGame1
EndGame1 Mar. 20 at 2:29 PM
$TAOX We closed that daily gap up from $5.80. Now back to $6's. Finally getting noticed.
0 · Reply
EndGame1
EndGame1 Mar. 20 at 1:44 AM
$TAOX And just like that. Never sell $TAO.X coin. Bittensor TAO Price #35 $279.70 23.6% (7d
0 · Reply
EndGame1
EndGame1 Mar. 19 at 2:26 PM
$TAOX Ugly couple of days. I'm just holding for the bounce back.
0 · Reply
Ineedbenjamins
Ineedbenjamins Mar. 18 at 6:45 PM
$TAOX Aixbt said this
0 · Reply
EndGame1
EndGame1 Mar. 18 at 4:14 PM
$TAOX Price is down, but $TAO.X coin still holding #38 spot. Was 55 a few weeks ago. Bittensor TAO Price #38 $268.52 35.2% (7d)
0 · Reply
TheRealSatoshiNakomoto
TheRealSatoshiNakomoto Mar. 18 at 2:12 AM
$TAOX how high can this go
1 · Reply
TaoistTrader
TaoistTrader Mar. 18 at 1:41 AM
$TAO.X $TAOX that dip was gobbled up 😂
0 · Reply
BEent
BEent Mar. 17 at 7:04 PM
$TAOX opened a position here. Own $TAO.X and will position into this as well for the long term
0 · Reply
TaoistTrader
TaoistTrader Mar. 17 at 2:46 PM
$TAO.X $TAOX agreed profit taking is healthy in fact. Stocks don’t go straight up
1 · Reply
EndGame1
EndGame1 Mar. 17 at 2:22 PM
$TAOX OT While I wait, another crypto holding $SBLX Almost no volume, but they collect coins too. LINK, Fluid, INJ and AAVE that I know of. All have been beat down. @jaltucher is running their coin collection. Waiting on their latest report.
0 · Reply
EndGame1
EndGame1 Mar. 17 at 1:56 PM
$TAOX $TAO.X Coin profit taking is part of the game. Here's your chance. This stock is going much, much higher imo.
0 · Reply
TaoistTrader
TaoistTrader Mar. 17 at 12:35 PM
$TAO.X $TAOX in @jaltucher we trust 🙏🏼
0 · Reply
DMAY0
DMAY0 Mar. 16 at 7:38 PM
$TAOX dah!! I wimped out bc of the trading prices twice! Oh well go TAO
1 · Reply
EndGame1
EndGame1 Mar. 16 at 7:07 PM
$TAOX Consider this 100% share price move off of the bottom was on no news from the company. Just on the back of $TAO.X coin move. At some point we get a report of how many coins TAO Synergies own and have stacked.
0 · Reply
EndGame1
EndGame1 Mar. 16 at 7:00 PM
$TAOX Oh well, tested $6.47 again. Maybe next time.
0 · Reply
EndGame1
EndGame1 Mar. 16 at 6:51 PM
$TAOX $6.47 was high of day. Gunning for it.
0 · Reply
EndGame1
EndGame1 Mar. 16 at 4:36 PM
$TAOX We knew this move was coming. I told many. As far as I know, nobody bought. Bittensor TAO Price #37 $286.84 47.4% (7d)
1 · Reply